Metastatic Bone Disease: Future Directions

Clinical Orthopaedics and Related Research

Volumn 415, Issue SUPPL., 2003, Pages

  Clohisy, Denis R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOSINE DEAMINASE; DRUG METABOLITE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GANCICLOVIR PHOSPHATE; HERPES SIMPLEX VIRUS THYMIDINE KINASE; NERVE GROWTH FACTOR RECEPTOR; PRODRUG; THYMIDINE KINASE; UNCLASSIFIED DRUG;

BONE CANCER; BONE METASTASIS; BYSTANDER EFFECT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; CONSERVATIVE TREATMENT; DRUG EFFECT; DRUG EFFICACY; DRUG TRANSFORMATION; ENZYME PRODRUG GENE THERAPY; GENE THERAPY; HUMAN; MUSCLE CANCER; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION;

EID: 0142157082     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000093056.96273.b2     Document Type: Conference Paper

References (21)

1. Clohisy D: Management of Skeletal Metastasis. In Edward V, Craig M (eds). Clinical Orthopaedics. Philadelphia, Lippincott Williams & Wilkins 994-997, 1999.
2. Clohisy DR, Ogilvie CM, Carpenter RJ, Ramnaraine ML: Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res 14:2-6, 1996.
3. Connors TA: The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 2:702-709, 1995.
4. Danielsen S, Kilstrup M, Barilla K, Jochimsen B, Neuhard J: Characterization of the Escherichia coli codBA operon encoding cytosine pennease and cytosine deaminase. Mol Microbiol 6:1335-1344, 1992.
5. Deonarain MP, Spooner RA, Epenetos AA: Genetic delivery of enzymes for cancer therapy. Gene Ther 2:235-244, 1995.
6. Domin BA, Mahony WB, Zimmerman TP: Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem Pharmacol 46:503-510, 1993.
7. Hayden MS, Linsley PS, Wallace AR, Marquardt H, Kerr DE: Cloning, overexpression, and purification of cytosine deaminase from Saccharomyces cerevisiae. Protein Expr Purif 12:173-184, 1998.
8. Holder JW, Elmore E, Barrett JC: Gap junction function and cancer. Cancer Res 53:3475-3485, 1993.
9. Hortobagyi GN, Theriault RL, Lipton A, et al: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044, 1998.
10. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785-1791, 1996.
11. Hotz-Wagenblatt A, Shalloway D: Gap junctional communication and neoplastic transformation. Crit Rev Oncol 4:541-558, 1993.
12. Huber BE, Austin EA, Richards CA, Davis ST, Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91:8302-8306, 1994.
13. Kievit E, Bershad E, Ng E, et al: Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 59:1417-1421, 1999.
14. Kievit E, Nyati MK, Ng E, et al: Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 60:6649-6655, 2000.
15. Lawrence TS, Davis MA, Maybaum J: Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 29:519-523, 1994.
16. Lawrence TS, Rehemtulla A, Ng EY, et al: Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res 58:2588-2593, 1998.
17. Lipton A, Theriault RL, Hortobagyi GN, et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082-1090, 2000.
18. Senter PD, Su PC, Katsuragi T, et al: Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug Chem 2:447-451, 1991.
19. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial: Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999.
20. Tong D, Gillick L, Hendrickson FR: The palliation of symptomatic osseous metastases: Final results of the Study by the Radiation Therapy Oncology Group. Cancer 50:893-899, 1982.
21. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE: Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55:4808-4812, 1995.